Rheumatic diseases are a group of diseases that affect joints, bones and their surrounding soft tissues, including rheumatoid arthritis, systemic lupus erythematosus, vasculitis, systemic sclerosis, osteoporosis and so on. At present, the treatment of rheumatism is mainly hormone and immunosuppressant, but the above drugs have serious side effects and take effect for a long time, so they have limitations for critical and critically ill patients. Therefore, scholars at home and abroad have carried out a new treatment scheme, that is, immunoadsorption therapy. Immunoadsorption (Immunoadsorption, IA) is a blood purification technique that combines highly specific antigens, antibodies or substances (ligands) with specific physical and chemical affinity with adsorption materials (carriers) to form adsorbents (columns) to selectively or specifically remove pathogenic immune complexes or autoantibodies from plasma to improve patients' clinical symptoms. IA has high safety and can effectively avoid the risk of transmission of infectious diseases or allergic reactions. At present, it is used in the clinical treatment of rheumatic diseases, hematological diseases, nervous system diseases and other diseases. This article reviews the application of immunoadsorption therapy for rheumatism in recent years.